Previous 10 | Next 10 |
Amryt Supports FH Awareness Day – September 24, 202 2 DUBLIN, Ireland, and Boston MA, September 2 3 , 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializi...
A committee of the European Medicines Agency (EMA) recommended the approval of Amryt's ( NASDAQ: AMYT ) Mycapssa (octreotide capsules) in the EU as a maintenance therapy of acromegaly in patients who have responded to and tolerated treatment with octreo...
CHMP a dopts p ositive o pinion for Mycapssa ® for the t reatment of Acromegaly Positive o pinion based on MPOWERED Phase 3 trial DUBLIN, Ireland, and Boston MA, September 1 6 ...
Irish commercial-stage biopharma Amryt ( NASDAQ: AMYT ) on Thursday said UK's drug regulator had approved its Filsuvez gel to treat wounds associated with genetic skin disorder epidermolysis bullosa (EB). U.S.-listed shares of AMYT were 3.5% higher at $7.93 in premarke...
Amryt R eceives Marketing Authorisation Approval and Orphan Drug Designation for Filsuvez® in Great Britain UK MHRA approval follows on from recent European Commission approval of Filsuvez® DUBLIN, Ireland, and Boston MA, S...
Amryt to Present Data from MPOWERED Phase 3 Trial of Mycapssa® (oral octreotide) at ENEA 2022 DUBLIN, Ireland, and Boston MA, September 7 , 202 2 , Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, develop...
Krystal Bio (KRYS) has performed well in the last two months that I have had it. Its B-VEC looks highly approvable. With Amryt's CRL, the competitive gap has widened in favor of Krystal. Krystal Biotech ( KRYS ) is up hugely since I first covered it earlier this year...
Amryt Pharma plc (AMYT) Q2 2022 Earnings Conference Call August 04, 2022 08:30 AM ET Company Participants Simon Loughrey - Group Financial Controller Joseph Wiley - Chief Executive Officer Rory Nealon - Chief Financial Officer and Chief Operating Officer Jord...
The following slide deck was published by Amryt Pharma plc in conjunction with their 2022 Q2 earnings call. For further details see: Amryt Pharma plc 2022 Q2 - Results - Earnings Call Presentation
Amryt Pharma press release ( NASDAQ: AMYT ): Q2 GAAP EPS of -$0.02 beats by $0.04 . Revenue of $68.54M (+9.2% Y/Y) beats by $4.28M . Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underwa...
News, Short Squeeze, Breakout and More Instantly...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland a...
Turnover at €2 billion 749 million, with growth of 13.6% over 2021 The European market remains at the center, with significant international development The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare disease...
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3 , 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq...